PhytoMedical Expands Scope of Patented Technology That Kills Cancer Cells
In response to the success of the studies, PhytoMedical’s collaborating scientists are now synthesizing and testing new derivatives of these anti-cancer agents. Further tests of the “DNA binding” anti-cancer agents are planned for human cancer cell lines specific to glioblastoma (tumors related to the brain) and small cell lung cancer, both of which are associated with a high mortality rate.
This entry was posted on Monday, December 31st, 2007 at 12:20 pm and is filed under Research, Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.